Enspryng (Satralizumab) is an interleukin-6 (IL-6) receptor antagonist used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Dosage: The recommended loading dosage of Satralizumab for the first three administrations is 120 mg by subcutaneous injection at 0, 2, & 4 Weeks, followed by a maintenance dosage of 120 mg every 4 weeks. Prior to every use of Satralizumab, advise patients to consult with their health specialist in case they suspect an active infection, including localized infections. In case of active infection, delay the use of Satralizumab until the infection is resolved.
Side Effects: The most commonly reported enspryng side effects (incidence at least 15%) include:
- Extremity pain
- Upper respiratory tract infection
Warnings and Precautions:
- The enspryng uses are restricted in patients with known hypersensitivity to satralizumab or any of the inactive ingredients, active Hepatitis B infection, or active/untreated latent tuberculosis.
- Live or live-attenuated vaccines should not be administered concurrently with enspryng dosing because clinical safety has not been established.
- The ALT and AST levels should be monitored every 4 weeks for the initial three months of therapy, followed by every three months for one year.
- Neutrophil counts should be monitored 4-8 weeks after initiation of therapy with satralizumab injection, and thereafter at regular clinically determined intervals.